Cryptotanshinone inhibits cytotoxin-associated gene A-associated development of gastric cancer and mucosal erosions

Table 1 Correlation between expression of phosphorylated Src homology 2 domain–containing phosphatase 2 and other clinicopathologic characteristics

Factors		Expression of p-SHP2		χ2		P value
		Positive, n (%)	Negative, n (%)
Age (yr)	≤ 60	11 (21.6)	6 (11.8)		0.308	0.579
	> 60	20 (39.2)	14 (27.5)
Gender	Male	24 (47.1)	16 (31.4)		0.000	1.0001
	Female	7 (13.7)	4 (7.8)
Tumor location	Cardia	18 (35.5)	9 (17.6)		0.833	0.361
	non-cardia	13 (25.5)	11 (21.6)
Differentiation	Well	11 (29.41)	12 (17.65)		2.951	0.086
	Poor	20 (17.65)	8 (35.29)
Tumor size	≥ 5 cm	18	18		5.972	0.015
	< 5 cm	13	2
T stage	T1-T2	7 (13.7)	15 (29.4)		13.618	0.000
	T3-T4	24 (47.1)	5 (9.8)
N stage	N0	8 (15.7)	15 (29.4)		11.882	0.001
	N1-N3	23 (45.1)	5 (9.8)
TNM stage	Ⅰ, Ⅱ	10 (19.6)	16 (31.4)		11.088	0.001
	Ⅲ, Ⅳ	21 (41.2)	4 (7.8)
CagA-IgG	Positive	18 (35.3)	4 (7.8)		7.181	0.007
	Negative	13 (25.5)	16 (31.4)

¹Continuity correction. CagA: Cytotoxin-associated gene A; IgG: Immunoglobulin G; TNM: Tumor-node-metastasis; SHP2: Src homology 2 domain–containing phosphatase 2.